

Crown Agents Ukraine - General Procurement Notice – addendum 9

Requirements for Programme 23 – Medicines for patients with viral Hepatitis B and C

International non-proprietary name	Form of presentation	Dosage	Estimated Demand, 100%	Estimated Quantity under the Assets Allocated
For Children with Viral Hepatitis B				
Tenofovir	tablet, capsule, pill	300 mg	7,805	7,805
Entecavir	—“—	1 mg	5,480	5,480
Entecavir	—“—	0.5 mg	9,279	9,279
Pegylated interferon alfa-2a	ampoule, vial, syringe	135 µg/0.5 ml	264	264
Pegylated interferon alfa-2a	—“—	180 µg /0.5 ml	155	155
For Adults with Viral Hepatitis B				
Tenofovir	tablet, capsule, pill	300 mg	226,940	226,940
Entecavir	—“—	1 mg	60,225	60,225
Entecavir	—“—	0.5 mg	10,950	10,950
Pegylated interferon alfa-2a	ampoule, vial, syringe	180 µg /0.5 ml	1,553	1,553
For Adults with Viral Hepatitis C				
Sofosbuvir	tablet, capsule, pill	400 mg	378,112	378,112
Daclatasvir	—“—	60 mg	382,312	382,312
Sofosbuvir / Velpatasvir	—“—	400 mg/100 mg	472,910	472,910
Sofosbuvir / Ledipasvir	—“—	400 mg/90 mg	124,796	124,796
For Children with Viral Hepatitis C				
Sofosbuvir	—“—	400 mg	1,807	1,807
Ribavirin	—“—	200 mg	24,812	24,812
Sofosbuvir / Ledipasvir	—“—	400 mg/90 mg	2,688	2,688
Pegylated interferon alfa-2a	ampoule, vial, syringe	135 µg /0.5 ml	1,028	1,028